WGS250117C65000
- 18.50
- +5.14+38.47%
GeneDx Holdings Newsroom
GeneDx Holdings Is Maintained at Buy by Craig-Hallum
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $95
GeneDx Hldgs Analyst Ratings
Wells Fargo Maintains GeneDx Holdings(WGS.US) With Hold Rating, Raises Target Price to $75
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $75
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $95
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $70
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $70
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Announces Target Price $70
GeneDx Hldgs Analyst Ratings
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $54
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
Craig-Hallum Issues a Buy Rating on GeneDx Holdings (WGS)
GeneDx Holdings Price Target Raised to $45.00/Share From $35.00 by BTIG
GeneDx Hldgs Analyst Ratings
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $46
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $45
Buy Rating Affirmed: GeneDx Holdings' Financial Growth and Promising Outlook Propel Stock's Upward Trajectory
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $50